Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

News

31 - 40of about 316 News

31 - 40of about 316 News

April 22, 2022

Not intended for U.S. and UK Media

Bayer submits application in China for additional indication of darolutamide

April 13, 2022

Not intended for U.S. and UK Media

Bayer receives approval for precision oncology treatment Vitrakvi™ in China

April 03, 2022

Not intended for U.S. and UK Media - American College of Cardiology’s 71st Annual Scientific Session (ACC.22):

Bayer presents positive results from first Phase 2b trial on safety of asundexian in patients with atrial fibrillation

April 01, 2022

Breakthrough Innovation Forum

Bayer set to drive breakthrough innovations in the Life Sciences

March 28, 2022

Not intended for U.S. and UK Media

Bayer receives approval in Japan for Kerendia™ (finerenone), a new treatment for adults with chronic kidney disease and type 2 diabetes

March 22, 2022

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

Bayer refinances 1.3 billion euro hybrid bond

March 11, 2022

Not intended for U.S. and UK Media

Bayer submits application for additional indication of Nubeqa™ (darolutamide) in Japan

March 10, 2022

Bayer to sell its Environmental Science Professional business to Cinven for 2.6 billion U.S. dollars

March 09, 2022

Not intended for U.S. and UK Media

Bayer submits applications in the U.S. and EU for additional indication of Nubeqa™ (darolutamide)

March 01, 2022

Fiscal 2021:

Bayer: Dynamic growth - progress in innovation

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases